The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 03, 2013

Filed:

Oct. 25, 2010
Applicants:

Djordje Atanackovic, Hamburg, DE;

Tim Luetkens, Hamburg, DE;

Inventors:

Djordje Atanackovic, Hamburg, DE;

Tim Luetkens, Hamburg, DE;

Assignee:

Other;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/00 (2006.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01); A61K 49/00 (2006.01); A61B 5/055 (2006.01); A01N 61/00 (2006.01); C12Q 1/00 (2006.01); C12Q 1/68 (2006.01); G01N 33/53 (2006.01); G01N 33/567 (2006.01); G01N 33/574 (2006.01);
U.S. Cl.
CPC ...
Abstract

The present invention relates to the field of diagnosis and therapy of hematological malignancies based on the tumor antigen FMR1NB (also called NY-SAR-35, Cancer/testis antigen 37 or Fragile X mental retardation 1 neighbor protein) and agents specifically targeting this antigen or cells expressing the same, e.g., antibodies. The inventors were able to prove that the molecule is expressed on the cell surface and thus represents a particularly advantageous target in cancer therapy and vaccination. Surprisingly, FMR1NB was found to be associated with hematological malignancies, e.g. acute myeloid leukemia (AML) or chronic myeloid leukemia (CML).


Find Patent Forward Citations

Loading…